Carol Hawkins, NP
Family · Knoxville, TNNPI 1639186109
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 73.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $6,313 and has fallen 81.4% since, to $1,176 in 2025. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $61.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$16K
- AstraZeneca$1K
- GSK$912
- Actelion Pharmaceuticals US, Inc.$618
- Insmed, Inc.$389
- Merck$291
- plus $2K from 25 others
What the payments were for
- Consulting fees$1,5607%
- Speaking & faculty fees$11,95855%
- Travel & lodging$1,2706%
- Food & beverage$7,05332%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 69 | $16,041 |
| AstraZeneca(2 entities) | 40 | $1,479 |
| GSK | 63 | $912 |
| Actelion Pharmaceuticals US, Inc. | 40 | $618 |
| Insmed, Inc. | 15 | $389 |
| Merck | 13 | $291 |
| Grifols USA, LLC | 18 | $287 |
| Regeneron Healthcare Solutions, Inc. | 14 | $276 |
| Sanofi | 13 | $259 |
| Amgen | 11 | $252 |
| United Therapeutics Corporation | 10 | $222 |
| AbbVie | 12 | $201 |
| Genentech USA, Inc. | 8 | $130 |
| Baxter Healthcare | 5 | $119 |
| Mylan Specialty L.p. | 5 | $77 |
| Verona Pharma, Inc. | 2 | $45 |
| Tactile Systems Technology Inc | 1 | $39 |
| Pfizer | 2 | $32 |
| Bayer | 2 | $29 |
| Johnson & Johnson | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Sandoz | 1 | $20 |
| Vapotherm Inc | 1 | $20 |
| Electromed, Inc. | 1 | $20 |
| Vertex | 1 | $19 |
| Novartis | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Gilead | 1 | $15 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,929 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 178 | $202,118 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 150 | $153,656 |
| Spiriva RespimatTiotropium Bromide | 57 | $47,228 |
| Dupixent PenDupilumab | 11 | $39,325 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $38,401 |
| SymbicortBudesonide/Formoterol Fumarate | 67 | $24,806 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $16,287 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $8,302 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 210 | $8,275 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,958 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $4,517 |
| Famotidine | 81 | $1,992 |
| Roflumilast | 24 | $1,986 |
| Ventolin HfaAlbuterol Sulfate | 24 | $1,982 |
| Azelastine Hcl | 38 | $1,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $912 | $225,363224 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,479 | $178,462217 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $16,041 | $85,629101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Knoxville
- Dana WebberKnoxville$499K
- Tiffany SipeKnoxville$87K
- Ashley BonnellKnoxville$49K
- Stacey MaltmanKnoxville$34K
- Katherine JohnsonKnoxville$32K
- Ashley BellKnoxville$22K
- Mina FarrarKnoxville$21K
- Amy AllenKnoxville$21K
- Sarah HarderKnoxville$19K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.